systemic lupus erythematosus

Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial

By MedXY 10/25/2025

This article reviews a pivotal phase 3 trial demonstrating telitacicept's efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.

$Innovative Allogeneic CD19-Targeting T Cells Show Promise in Refractory Systemic Lupus Erythematosus with Lupus Nephritis$

Allergy & Immunology Clinical Updates Rheumatology Specialties

Innovative Allogeneic CD19-Targeting T Cells Show Promise in Refractory Systemic Lupus Erythematosus with Lupus Nephritis

By MedXY 09/04/2025

A phase 1 trial demonstrates that the allogeneic CD19-targeting T cell therapy YTS109 is safe and induces clinical remission, immune resetting, and renal tissue restoration in patients with refractory systemic lupus erythematosus complicated by lupus nephritis.

Allergy & Immunology Medical News news Rheumatology Specialties

Fine Particulate Matter Exposure Significantly Increases SLE Risk

By MedXY 08/04/2025

A large Taiwanese cohort study links higher PM2.5 exposure to a more than threefold increased risk of developing systemic lupus erythematosus, underscoring the need for air quality policy interventions.

Allergy & Immunology Clinical Updates news Rheumatology Specialties

Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial

By MedXY 08/03/2025

A 4-year phase 3 extension study shows that anifrolumab improves patient-reported outcomes and quality of life in systemic lupus erythematosus, with a favorable safety profile.